Antithrombotic and antiallergic activities of XXXX from Rhei Rhizoma are activated by human intestinal bacteria.

@entity1423 @entity19 @entity117 @entity40974 @entity70964 @entity10814 @entity35 @entity715 @entity857
To evaluate the antithrombotic and antiallergic properties of @entity40974 extracted from Rhei Rhizoma, the in vitro and ex vivo inhibitory activities of @entity40974 and its metabolite, @entity70964 , were measured. These compounds inhibited in vitro @entity857 - and collagen-induced @entity1423 . @entity70964 was more potent, with IC50 values of 4 and 70 microg/ml, respectively. In ex vivo @entity857 - and collagen-induced @entity35 @entity1423 , these compounds also exhibited a potent inhibitory effect. The antiplatelet aggregation effects of @entity40974 and @entity70964 were more potent than those of @entity117 . @entity70964 showed significant protection from death due to @entity715 in @entity19 . @entity70964 also showed the strongest inhibitory activity against @entity10814 release induced by DNP-BSA. These compounds inhibited PCA reaction in @entity19 . @entity70964 intraperitoneally administered showed the strongest inhibitory activity and significantly inhibited PCA at doses of 25 and 50 mg/kg, with inhibitory activities of 48 and 85%, respectively. The inhibitory activity of orally administered @entity40974 was stronger than that of intraperitoneally administered @entity40974 . These results suggest that @entity40974 , in the rhizome of Rhei Rhizoma, is a prodrug that has extensive antiallergic and antithrombotic properties.
